Get the Stockscreener App
50.82
1.96%
0.9984
Enliven Therapeutics Inc stock is traded at $50.82, with a volume of 398.97K.
It is up +1.96% in the last 24 hours and up +46.35% over the past month.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
See More
Previous Close:
$49.82
Open:
$49.57
24h Volume:
398.97K
Relative Volume:
0.29
Market Cap:
$3.63B
Revenue:
-
Net Income/Loss:
$-98.78M
P/E Ratio:
-30.54
EPS:
-1.6638
Net Cash Flow:
$-65.60M
1W Performance:
-0.10%
1M Performance:
+46.35%
6M Performance:
+235.51%
1Y Performance:
+145.04%
1-Day Range:
$49.46
$51.39
1-Week Range:
$47.45
$52.39
52-Week Range:
$14.79
$52.39
Enliven Therapeutics Inc Stock (ELVN) Company Profile
Name
Enliven Therapeutics Inc
Sector
Industry
Phone
720-647-8519
Address
6200 LOOKOUT ROAD, BOULDER
Compare ELVN vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELVN
Enliven Therapeutics Inc
|
50.74 | 3.63B | 0 | -98.78M | -65.60M | -1.6638 |
VRTX
Vertex Pharmaceuticals Inc
|
528.70 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
647.99 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
926.39 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.73 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.24 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-16-25 | Initiated | Goldman | Buy |
| Dec-13-24 | Initiated | BTIG Research | Buy |
| Sep-09-24 | Initiated | H.C. Wainwright | Buy |
| Jun-11-24 | Initiated | Robert W. Baird | Outperform |
| Apr-09-24 | Initiated | Mizuho | Buy |
| Mar-29-23 | Initiated | Jefferies | Buy |
View All
Enliven Therapeutics Inc Stock (ELVN) Latest News
ELVN Maintained by Stifel -- Price Target Raised to $80 - GuruFocus
Medical Hedge Fund Sells 281,000 Shares of Enliven Theapeutics. Is it Time to Sell ELVN? - AOL.com
ELVN Maintained by Jones Trading -- Price Target Raised to $70.0 - GuruFocus
Jones Trading raises Enliven Therapeutics price target on CML trials By Investing.com - Investing.com South Africa
Enliven Therapeutics, Inc.(NasdaqGS:ELVN) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
Jones Trading raises Enliven Therapeutics price target on CML trials - Investing.com
Enliven Therapeutics, Inc.(NasdaqGS:ELVN) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Enliven Therapeutics, Inc.(NasdaqGS: ELVN) dropped from Russell Microcap Index - marketscreener.com
Enliven Therapeutics, Inc.(NasdaqGS: ELVN) dropped from Russell 3000E Index - marketscreener.com
What to Know About This $345,000 Enliven Insider Sale as the Stock Soars 130% - Yahoo Finance
What to Know About OrbiMed's $39 Million Enliven Therapeutics Stock Sale Amid a 130% Rally - AOL.com
What to Know About OrbiMed's $39 Million Enliven Therapeutics Stock Sale Amid a 130% Rally - The Motley Fool
Enliven Therapeutics, Inc. Actuals & Estimates (NASDAQ:ELVN) - TradingView
ELVN Forecast — Price Target — Prediction for 2027 - TradingView
(ELVN) and the Role of Price-Sensitive Allocations - Stock Traders Daily
22% Below Analyst Target, Is Enliven Therapeutics (ELVN) Fairly Valued Here - Sahm
OrbiMed entities sell $39 million in Enliven Therapeutics stock By Investing.com - Investing.com Nigeria
Enliven Therapeutics(ELVN.US) 10% Shareholder Sells US$39.01 Million in Common Stock - Moomoo
Form 4 Enliven Therapeutics Inc For: 24 June By Investing.com - Investing.com South Africa
OrbiMed entities sell $39 million in Enliven Therapeutics stock - Investing.com UK
Form 13D/A Enliven Therapeutics For: 24 June By Investing.com - Investing.com South Africa
OrbiMed funds trim Enliven Therapeutics (NASDAQ: ELVN) stake with 860K-share sale - Stock Titan
OrbiMed cuts Enliven Therapeutics (ELVN) holdings to 9.5% of shares - Stock Titan
ETFs Investing in Enliven Therapeutics, Inc. Stocks - TradingView
Enliven Therapeutics stock hits 52-week high at 48.55 USD By Investing.com - Investing.com India
Enliven Therapeutics stock hits 52-week high at 48.55 USD - Investing.com UK
Enliven Therapeutics CFO Hohl sells $263,577 in stock By Investing.com - Investing.com India
Enliven Therapeutics CMO sells $219,016 in shares By Investing.com - Investing.com India
ELVN (Nasdaq) affiliate sales noted; OrbiMed sold 9,086 shares - Stock Titan
Form 144 Enliven Therapeutics For: 22 June By Investing.com - Investing.com Nigeria
Form 144 | Enliven Therapeutics(ELVN.US) Insider Proposes to Sell 38.32 Million in Common Stocks - Moomoo
Enliven Therapeutics Insider Sold Shares Worth $263,577, According to a Recent SEC Filing - Moomoo
Enliven Therapeutics CFO Hohl sells $263,577 in stock - Investing.com UK
Enliven Therapeutics CMO sells $219,016 in shares - Investing.com UK
Form 4 Enliven Therapeutics Inc For: 22 June By Investing.com - Investing.com Nigeria
Enliven Therapeutics Inc Stock (ELVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.72%
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):